Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132).
作者
D. Ross Camidge,Rebecca Suk Heist,Gregory A. Masters,Ronald J Scheff,Alexander Starodub,Wells A. Messersmith,Aditya Bardia,Allyson J. Ocean,Leora Horn,Jordan D. Berlin,Pius P. Maliakal,Robert M. Sharkey,Francois E. Wilhelm,David M. Goldenberg,Michael J. Guarino
9011 Background: Sacituzumab govitecan (IMMU-132) is an ADC comprising SN-38, the active metabolite of the topoisomerase inhibitor, irinotecan, conjugated to an anti-Trop-2 humanized mAb. In vitro and in vivopreclinical data show that this ADC is efficacious with a high drug:antibody ratio of 7.6, and capable of delivering up to 136-fold more SN-38 than its parent drug, irinotecan, in a human cancer xenograft. The mAb and ADC are immunotherapeutic in vitro (ADCC). Trop-2 expression is increased in most epithelial cancers (>80%), including NSCLC. Therefore, the efficacy and safety of this new ADC is being examined in mNSCLC patients (pts) with > 1st line therapy. Methods: An expansion cohort from a Phase I/II clinical trial (ClinicalTrials.gov, NCT01631552) is enrolling >1st line mNSCLC pts, administering IMMU-132 on days 1 and 8 of 21-day treatment cycles. Treatment continues based on tolerance or until progression, with safety and response (RECIST 1.1) assessments made weekly and every 8 weeks, respectively. Results: Forty-five mNSCLC pts were enrolled by 11/19/15. Thirty-four are assessable [median age 62.5 yrs, 21 M/13 F, ECOG 0 (N=4)/1 (N=29)/unknown (N=1)], with a median of 3 (range, 1-7) prior lines of chemotherapy. All pts received prior treatment with platinum-based therapy. Pts were given IMMU-132 doses of 8 mg/kg (N =9) or 10 mg/kg (N =25). Tumor responses are shown in the Table. Among adverse events collected so far (n=24), grade >3 drug-related toxicities above 5% incidence are diarrhea (8%) and neutropenia (8%). No patient developed antibodies (by ELISA) to the antibody or drug. Conclusions: Objective responses and good tolerability encourage further study of IMMU-132 in mNSCLC pts with > 1st line therapy. Clinical trial information: NCT01631552.IMMU-132 Dosage Objective Response Rate (PR) , including confirmed and unconfirmed Clinical benefit (PR+ SD > 6 Months) Median Progression-Free Survival (Months) (% maturity) Median Overall Survival (Months) (% maturity) 8 mg/kg (N=9) 37% 50% 4.2 (67%) Not Reached (44%) 10 mg/kg (N=25) 29% 33% 3.8 (68%) Not Reached (8%) Both doses (N=34) 31% 35% 3.9 (68%) Not Reached (18%)